Skip to main content
PMC home page
The AAPS Journal logoLink to The AAPS Journal
. 2006 Nov 17;8(4):E693–E708. doi: 10.1208/aapsj080479

Endocannabinoid mechanisms of pain modulation

Andrea G Hohmann 1,✉, Richard L Suplita 1
PMCID: PMC2751366  PMID: 17233533

Abstract

Cannabinoids are antinociceptive in animal models of acute, tissue injury-, and nerve injury-induced nociception. This review examines the biology of endogenous cannabinoids (endocannabinoids) and behavioral, neurophysiological, and neuroanatomical evidence supporting the notion that cannabioids play a role in pain modulation. Behavioral pharmacological approaches, in conjunction with the identification and quantification of endocannabinoids through the use of liquid and gas chromatography mass spectrometry, have providedinsight into the functional roles of endocannabinoids in pain modulation. Here we examine the distribution of cannabinoid receptors and endocannabinoid-hydrolyzing enzymes within pain modulatory circuits together with behavioral, neurochemical, and neurophysiological studies that suggest a role for endocannabinoid signaling in pain modulation. This review will provide a comprehensive evaluation of the roles of the endocannabinoids 2-arachidonoyl-glycerol and anandamide in stress-induced analgesia. These findings provide a functional framework with which to understand the roles of endocannabinoids in nociceptive processing at the supraspinal level.

Keywords: 2-arachidonoylglycerol, anandamide, CB1, fatty acid amide hydrolase, monoacylglycerol lipase, periaqueductal gray, rostral ventromedial medulla

Full Text

The Full Text of this article is available as a PDF (356.3 KB).

References

  • 1.Gerard CM, Mollerau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J. 1991;279:129–134. doi: 10.1042/bj2790129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11:563–583. doi: 10.1523/JNEUROSCI.11-02-00563.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–564. doi: 10.1038/346561a0. [DOI] [PubMed] [Google Scholar]
  • 4.Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949. doi: 10.1126/science.1470919. [DOI] [PubMed] [Google Scholar]
  • 5.Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995;50:83–90. doi: 10.1016/0006-2952(95)00109-D. [DOI] [PubMed] [Google Scholar]
  • 6.Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89–97. doi: 10.1006/bbrc.1995.2437. [DOI] [PubMed] [Google Scholar]
  • 7.Tsou K, Brown S, Sanudo-Peña MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1997;83:393–411. doi: 10.1016/S0306-4522(97)00436-3. [DOI] [PubMed] [Google Scholar]
  • 8.Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396:141–149. doi: 10.1016/S0014-2999(00)00211-9. [DOI] [PubMed] [Google Scholar]
  • 9.Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA. 1999;96:5780–5785. doi: 10.1073/pnas.96.10.5780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54–61. doi: 10.1111/j.1432-1033.1995.tb20780.x. [DOI] [PubMed] [Google Scholar]
  • 11.Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65. doi: 10.1038/365061a0. [DOI] [PubMed] [Google Scholar]
  • 12.Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142:278–287. doi: 10.1006/taap.1996.8034. [DOI] [PubMed] [Google Scholar]
  • 13.Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci. 2003;17:2750–2754. doi: 10.1046/j.1460-9568.2003.02704.x. [DOI] [PubMed] [Google Scholar]
  • 14.Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48:443–450. [PubMed] [Google Scholar]
  • 15.Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 1986;29:307–313. [PubMed] [Google Scholar]
  • 16.Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol. 1992;106:231–232. doi: 10.1111/j.1476-5381.1992.tb14321.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA. 1992;89:3825–3829. doi: 10.1073/pnas.89.9.3825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci. 1995;15:6552–6561. doi: 10.1523/JNEUROSCI.15-10-06552.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Deadwyler SA, Hampson RE, Mu J, Whyte A, Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther. 1995;273:734–743. [PubMed] [Google Scholar]
  • 20.Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids. 2002;121:173–190. doi: 10.1016/S0009-3084(02)00154-8. [DOI] [PubMed] [Google Scholar]
  • 21.Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. In: Pertwee R, editor. Cannabinoids—Handbook of Experimental Pharmacology. Berlin, Germany: Springer; 2005. pp. 509–554. [DOI] [PubMed] [Google Scholar]
  • 22.Malan TP, Ibrahim MM, Deng H, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 2001;93:239–245. doi: 10.1016/S0304-3959(01)00321-9. [DOI] [PubMed] [Google Scholar]
  • 23.Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998;394:277–281. doi: 10.1038/28393. [DOI] [PubMed] [Google Scholar]
  • 24.Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain. 2002;96:253–260. doi: 10.1016/S0304-3959(01)00454-7. [DOI] [PubMed] [Google Scholar]
  • 25.Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96:14228–14233. doi: 10.1073/pnas.96.25.14228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther. 2003;308:446–453. doi: 10.1124/jpet.103.060079. [DOI] [PubMed] [Google Scholar]
  • 27.Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 2003;119:747–757. doi: 10.1016/S0306-4522(03)00126-X. [DOI] [PubMed] [Google Scholar]
  • 28.Nackley AG, Suplita RL, Hohman AG. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 2003;117:659–670. doi: 10.1016/S0306-4522(02)00870-9. [DOI] [PubMed] [Google Scholar]
  • 29.Quartilho A, Mata HP, Ibrahim MM, et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology. 2003;99:955–960. doi: 10.1097/00000542-200310000-00031. [DOI] [PubMed] [Google Scholar]
  • 30.Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM 1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA. 2003;100:10529–10533. doi: 10.1073/pnas.1834309100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A, Porreca F. Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem Phys Lipids. 2002;121:191–200. doi: 10.1016/S0009-3084(02)00155-X. [DOI] [PubMed] [Google Scholar]
  • 32.Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids. 2002;66:243–256. doi: 10.1054/plef.2001.0362. [DOI] [PubMed] [Google Scholar]
  • 33.Walker JM, Huang SM. Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids. 2002;66:235–242. doi: 10.1054/plef.2001.0361. [DOI] [PubMed] [Google Scholar]
  • 34.Walker JM, Strangman NM, Huang SM. Cannabinoids and pain. Pain Res Manag. 2001;6:74–79. doi: 10.1155/2001/413641. [DOI] [PubMed] [Google Scholar]
  • 35.Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388:773–778. doi: 10.1038/42015. [DOI] [PubMed] [Google Scholar]
  • 36.Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873–884. doi: 10.1038/nrn1247. [DOI] [PubMed] [Google Scholar]
  • 37.Gauldie SD, McQueen DS, Pertwee R, Chessell IP. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br J Pharmacol. 2001;132:617–621. doi: 10.1038/sj.bjp.0703890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Smart D, Gunthorpe MJ, Jerman JC, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) Br J Pharmacol. 2000;129:227–230. doi: 10.1038/sj.bjp.0703050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hogestatt ED, Zygmunt PM, Petersson J, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452–457. doi: 10.1038/22761. [DOI] [PubMed] [Google Scholar]
  • 40.Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther. 1998;284:1209–1217. [PubMed] [Google Scholar]
  • 41.Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther. 1994;270:219–227. [PubMed] [Google Scholar]
  • 42.Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol. 2001;425:189–196. doi: 10.1016/S0014-2999(01)01182-7. [DOI] [PubMed] [Google Scholar]
  • 43.Jung K-M, Mangieri R, Stapleton C, et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol. 2005;68:1196–1202. doi: 10.1124/mol.105.013961. [DOI] [PubMed] [Google Scholar]
  • 44.Sugiura T. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues and related compounds. J Biol Chem. 1999;274:2794–2801. doi: 10.1074/jbc.274.5.2794. [DOI] [PubMed] [Google Scholar]
  • 45.Sugiura T. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. J Biol Chem. 2000;275:605–612. doi: 10.1074/jbc.275.1.605. [DOI] [PubMed] [Google Scholar]
  • 46.Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoylglycerol cannabinoid activity. Eur J Pharmacol. 1998;353:23–31. doi: 10.1016/S0014-2999(98)00392-6. [DOI] [PubMed] [Google Scholar]
  • 47.Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83–87. doi: 10.1038/384083a0. [DOI] [PubMed] [Google Scholar]
  • 48.Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 1993;46:791–796. doi: 10.1016/0006-2952(93)90486-G. [DOI] [PubMed] [Google Scholar]
  • 49.Di Marzo V, Bisogno T, Melck D, et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 1998;436:449–454. doi: 10.1016/S0014-5793(98)01175-2. [DOI] [PubMed] [Google Scholar]
  • 50.Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicinlike substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA. 2002;99:8400–8405. doi: 10.1073/pnas.122196999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl Acad Sci USA. 2002;99:10819–10824. doi: 10.1073/pnas.152334899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005;435:1108–1112. doi: 10.1038/nature03658. [DOI] [PubMed] [Google Scholar]
  • 53.Egertová M, Cravatt BF, Elphick MR. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide of endocannabinoid signaling. Neuroscience. 2003;119:481–496. doi: 10.1016/S0306-4522(03)00145-3. [DOI] [PubMed] [Google Scholar]
  • 54.Egertov M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B Biol Sci. 1998;265:2081–2085. doi: 10.1098/rspb.1998.0543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Tsou K, Nogueron MI, Muthian S, et al. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett. 1998;254:137–140. doi: 10.1016/S0304-3940(98)00700-9. [DOI] [PubMed] [Google Scholar]
  • 56.Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410:588–592. doi: 10.1038/35069076. [DOI] [PubMed] [Google Scholar]
  • 57.Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296:678–682. doi: 10.1126/science.1063545. [DOI] [PubMed] [Google Scholar]
  • 58.Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylgly cerol, another cannabinoid receptor ligand. FEBS Lett. 1998;422:69–73. doi: 10.1016/S0014-5793(97)01603-7. [DOI] [PubMed] [Google Scholar]
  • 59.Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre-and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20:441–458. doi: 10.1111/j.1460-9568.2004.03428.x. [DOI] [PubMed] [Google Scholar]
  • 60.Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol. 2004;66:1260–1264. doi: 10.1124/mol.104.002071. [DOI] [PubMed] [Google Scholar]
  • 61.Lichtman AH, Hawkins EG, Griffin G, Cravatt BF. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther. 2002;302:73–79. doi: 10.1124/jpet.302.1.73. [DOI] [PubMed] [Google Scholar]
  • 62.Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401–404. doi: 10.1126/science.283.5400.401. [DOI] [PubMed] [Google Scholar]
  • 63.Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 2001;98:9371–9376. doi: 10.1073/pnas.161191698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA. 2004;101:10821–10826. doi: 10.1073/pnas.0401292101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR14176A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240–244. doi: 10.1016/0014-5793(94)00773-X. [DOI] [PubMed] [Google Scholar]
  • 66.Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther. 1996;278:989–999. [PubMed] [Google Scholar]
  • 67.Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands. Chem. Phys Lipids. 2002;121:3–19. doi: 10.1016/S0009-3084(02)00143-3. [DOI] [PubMed] [Google Scholar]
  • 68.Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9:76–81. doi: 10.1038/nm803. [DOI] [PubMed] [Google Scholar]
  • 69.Bisogno T, Melck D, De Petrocellis L, et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun. 1998;248:515–522. doi: 10.1006/bbrc.1998.8874. [DOI] [PubMed] [Google Scholar]
  • 70.Makara JK, Mor M, Fegley D, et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci. 2005;8:1139–1141. doi: 10.1038/nn1521. [DOI] [PubMed] [Google Scholar]
  • 71.Kozak KR, Prusakiewicz JJ, Marnett LJ. Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des. 2004;10:659–667. doi: 10.2174/1381612043453081. [DOI] [PubMed] [Google Scholar]
  • 72.Moore SA, Nomikos GG, Dickason-Chesterfield AK, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci USA. 2005;102:17852–17857. doi: 10.1073/pnas.0507470102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Jarrahian A, Manna S, Edgemond WS, Campbell WB, Hillard CJ. Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J Neurochem. 2000;74:2597–2606. doi: 10.1046/j.1471-4159.2000.0742597.x. [DOI] [PubMed] [Google Scholar]
  • 74.Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277:1094–1097. doi: 10.1126/science.277.5329.1094. [DOI] [PubMed] [Google Scholar]
  • 75.De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 2000;483:52–56. doi: 10.1016/S0014-5793(00)02082-2. [DOI] [PubMed] [Google Scholar]
  • 76.Dixon WE. The pharmacology of cannabis. Indica Brit Med J. 1899;2:1354–1357. [Google Scholar]
  • 77.Bicher HI, Mechoulam R. Pharmacological effects of two active constituents of marihuana. Arch Int Pharmacodyn Ther. 1968;172:24–31. [PubMed] [Google Scholar]
  • 78.Kosersky DS, Dewey WL, Harris LS. Antipyretic, analgesic and anti-inflammatory effects of delta 9-tetrahydrocannabinol in the rat. Eur J Pharmacol. 1973;24:1–7. doi: 10.1016/0014-2999(73)90107-6. [DOI] [PubMed] [Google Scholar]
  • 79.Bloom AS, Dewey WL, Harris LS, Brosius KK. 9-nor-9beta-hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine. J Pharmacol Exp Ther. 1977;200:263–270. [PubMed] [Google Scholar]
  • 80.Buxbaum DM. Analgesic activity of 9-tetrahydrocannabinol in the rat and mouse. Psychopharmacologia. 1972;25:275–280. doi: 10.1007/BF00422507. [DOI] [PubMed] [Google Scholar]
  • 81.Martin BR, Compton DR, Thomas BF, et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav. 1991;40:471–478. doi: 10.1016/0091-3057(91)90349-7. [DOI] [PubMed] [Google Scholar]
  • 82.Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci. 2000;12:2079–2086. doi: 10.1046/j.1460-9568.2000.00101.x. [DOI] [PubMed] [Google Scholar]
  • 83.Harris J, Drew LJ, Chapman V. Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport. 2000;11:2817–2819. doi: 10.1097/00001756-200008210-00041. [DOI] [PubMed] [Google Scholar]
  • 84.Hohmann AG, Martin WJ, Tson K, Walker JM. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN. Life Sci. 1995;56:2111–2118. doi: 10.1016/0024-3205(95)00196-D. [DOI] [PubMed] [Google Scholar]
  • 85.Hohmann AG, Tson K, Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lum bar dorsal horn of the rat by spinally administered WIN55, 212-2. Neurosci Lett. 1998;257:119–122. doi: 10.1016/S0304-3940(98)00802-7. [DOI] [PubMed] [Google Scholar]
  • 86.Hohmann AG, Tsou K, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol. 1999;81:575–583. doi: 10.1152/jn.1999.81.2.575. [DOI] [PubMed] [Google Scholar]
  • 87.Kelly S, Chapman V. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol. 2001;86:3061–3064. doi: 10.1152/jn.2001.86.6.3061. [DOI] [PubMed] [Google Scholar]
  • 88.Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci. 1996;16:6601–6611. doi: 10.1523/JNEUROSCI.16-20-06601.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature. 1998;395:381–384. doi: 10.1038/26481. [DOI] [PubMed] [Google Scholar]
  • 90.Strangman NM, Walker JM. Cannabinoid WIN 55, 212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. Neurophysiol. 1998;82:472–477. doi: 10.1152/jn.1999.82.1.472. [DOI] [PubMed] [Google Scholar]
  • 91.Hohmann AG, Tsou K, Walker JM. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Acta Pharmacol Sin. 1999;20:1132–1136. [PubMed] [Google Scholar]
  • 92.Tsou K, Lowitz KA, Hohmann AG, et al. Suppression of noxious stimulus-evoked expression of FOS protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 1996;70:791–798. doi: 10.1016/S0306-4522(96)83015-6. [DOI] [PubMed] [Google Scholar]
  • 93.Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci. 2004;20:2311–2320. doi: 10.1111/j.1460-9568.2004.03690.x. [DOI] [PubMed] [Google Scholar]
  • 94.Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature. 1987;328:632–634. doi: 10.1038/328632a0. [DOI] [PubMed] [Google Scholar]
  • 95.Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain. 2002;97:11–21. doi: 10.1016/S0304-3959(01)00419-5. [DOI] [PubMed] [Google Scholar]
  • 96.Martin WJ, Loo CM, Basbaum AI. Spinal cannabinoids are antiallodynic in rats with persistent inflammation. Pain. 1999;82:199–205. doi: 10.1016/S0304-3959(99)00045-7. [DOI] [PubMed] [Google Scholar]
  • 97.Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 2003;119:747–757. doi: 10.1016/S0306-4522(03)00126-X. [DOI] [PubMed] [Google Scholar]
  • 98.Finn DP, Jhaveri MD, Beckett SR, et al. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology. 2003;45:594–604. doi: 10.1016/S0028-3908(03)00235-1. [DOI] [PubMed] [Google Scholar]
  • 99.Maione S, Bisogno T, de Novellis V, et al. Elevation of endocannabinoid levels in the ventrolaterial periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both CB1 and TRPV1 receptors. J Pharmacol Exp Ther. 2005;316:969–982. doi: 10.1124/jpet.105.093286. [DOI] [PubMed] [Google Scholar]
  • 100.Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res. 2003;987:176–185. doi: 10.1016/S0006-8993(03)03324-9. [DOI] [PubMed] [Google Scholar]
  • 101.Herzberg U, Eliav E, Dorsey JM, Gracely RH, Kopin IJ. NGF involvement in pain induced by chronic constriction injury of the rat sciatic nerve. Neuroreport. 1997;8:1613–1618. doi: 10.1097/00001756-199705060-00012. [DOI] [PubMed] [Google Scholar]
  • 102.Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 2001;133:586–594. doi: 10.1038/sj.bjp.0704110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Mao J, Price DD, Lu J, Keniston L, Mayer DJ. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett. 2000;280:13–16. doi: 10.1016/S0304-3940(99)00998-2. [DOI] [PubMed] [Google Scholar]
  • 104.Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci. 2000;15:510–521. doi: 10.1006/mcne.2000.0844. [DOI] [PubMed] [Google Scholar]
  • 105.Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11–23. doi: 10.1016/0304-3959(88)90198-4. [DOI] [PubMed] [Google Scholar]
  • 106.Chapman V. Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology. 2001;41:870–877. doi: 10.1016/S0028-3908(01)00125-3. [DOI] [PubMed] [Google Scholar]
  • 107.Fox A, Kesingland A, Gentry C, et al. The role of central and peripheral Cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 2001;92:91–100. doi: 10.1016/S0304-3959(00)00474-7. [DOI] [PubMed] [Google Scholar]
  • 108.Monhemius R, Azami J, Green DL, Roberts MH. CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res. 2001;908:67–74. doi: 10.1016/S0006-8993(01)02605-1. [DOI] [PubMed] [Google Scholar]
  • 109.Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol. 1997;334:R1–R2. doi: 10.1016/S0014-2999(97)01160-6. [DOI] [PubMed] [Google Scholar]
  • 110.Rice AS, Beaulieu P, Bisogno T, et al. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol. 2000;396:85–92. doi: 10.1016/S0014-2999(00)00226-0. [DOI] [PubMed] [Google Scholar]
  • 111.Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther. 1991;258:517–523. [PubMed] [Google Scholar]
  • 112.Martin WJ, Lai NK, Patrick SL, Tsou K, Walker JM. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 1993;629:300–304. doi: 10.1016/0006-8993(93)91334-O. [DOI] [PubMed] [Google Scholar]
  • 113.Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther. 1996;276:585–593. [PubMed] [Google Scholar]
  • 114.Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 1999;822:237–242. doi: 10.1016/S0006-8993(98)01368-7. [DOI] [PubMed] [Google Scholar]
  • 115.Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life. Sci. 1995;56:2103–2109. doi: 10.1016/0024-3205(95)00195-C. [DOI] [PubMed] [Google Scholar]
  • 116.Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett. 1998;242:33–36. doi: 10.1016/S0304-3940(98)00044-5. [DOI] [PubMed] [Google Scholar]
  • 117.Finn DP, Jhaveri MD, Beckett SR, Kendall DA, Marsden CA, Chapman V. Cannabinoids modulate ultrasound-induced aversive responses in rats. Psychopharmacology (Berl) 2004;172:41–51. doi: 10.1007/s00213-003-1629-1. [DOI] [PubMed] [Google Scholar]
  • 118.Cannon JT, Prieto GJ, Lee A, Liebeskind JC. Evidence for opioid and non-opioid forms of stimulation-produced analgesia in the rat. Brain Res. 1982;243:315–321. doi: 10.1016/0006-8993(82)90255-4. [DOI] [PubMed] [Google Scholar]
  • 119.Reynolds DV. Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science. 1969;164:444–445. doi: 10.1126/science.164.3878.444. [DOI] [PubMed] [Google Scholar]
  • 120.Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA. 1999;96:12198–12203. doi: 10.1073/pnas.96.21.12198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Suplita RL, Farthing JN, Gutierrez T, Hohmann AG. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology. 2005;49:1201–1209. doi: 10.1016/j.neuropharm.2005.07.007. [DOI] [PubMed] [Google Scholar]
  • 122.Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol. 2000;57:288–295. [PubMed] [Google Scholar]
  • 123.Palazzo E, Marabese I, de Novellis V, et al. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology. 2001;40:319–326. doi: 10.1016/S0028-3908(00)00160-X. [DOI] [PubMed] [Google Scholar]
  • 124.Vaughan CW, McGregor IS, Christie MJ. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol. 1999;127:935–940. doi: 10.1038/sj.bjp.0702636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Meng ID, Johansen JP. Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience. 2004;124:685–693. doi: 10.1016/j.neuroscience.2003.10.001. [DOI] [PubMed] [Google Scholar]
  • 126.Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry. 2001;6:13–34. doi: 10.1038/sj.mp.4000812. [DOI] [PubMed] [Google Scholar]
  • 127.Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530–534. doi: 10.1038/nature00839. [DOI] [PubMed] [Google Scholar]
  • 128.Medina JF, Repa CJ, Mauk MD, LeDoux JE. Parallels between cerebellum-and amygdala-dependent conditioning. Nat Rev Neurosci. 2002;3:122–131. doi: 10.1038/nrn728. [DOI] [PubMed] [Google Scholar]
  • 129.Helmstetter FJ, Bellgowan PS, Poore LH. Microinfusion of mu, but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats. J Pharm Exp Ther. 1995;275:381–388. [PubMed] [Google Scholar]
  • 130.Helmstetter FJ, Bellgowan PS, Tershner SA. Modulation of spinal nociceptive reflexes by the microinjection of morphine into the amygdala. Neuroreport. 1993;4:471–474. doi: 10.1097/00001756-199305000-00002. [DOI] [PubMed] [Google Scholar]
  • 131.Manning BH, Mayer DJ. The central nucleus of the amygdala contributes to the production of morphine antinociception in the rat tailflick test. J Neurosci. 1995;15:8199–8213. doi: 10.1523/JNEUROSCI.15-12-08199.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Manning BH, Merin NM, Meng ID, Amaral DG. Reduction in opioid-and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex. J Neurosci. 2001;21:8238–8246. doi: 10.1523/JNEUROSCI.21-20-08238.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Manning BH, Martin WJ, Meng ID. The rodent amygdala contributes to the production of cannabinoid-induced antinociception. Neuroscience. 2003;120:1157–1170. doi: 10.1016/S0306-4522(03)00356-7. [DOI] [PubMed] [Google Scholar]
  • 134.Helmstetter FJ. The amygdala is essential for the expression of conditional hypoalgesia. Behav Neurosci. 1992;106:518–528. doi: 10.1037/0735-7044.106.3.518. [DOI] [PubMed] [Google Scholar]
  • 135.Helmstetter FJ, Bellgowan PS. Lesions of the amygdala block conditional hypoalgesia on the tail flick test. Brain Res. 1993;612:253–257. doi: 10.1016/0006-8993(93)91669-J. [DOI] [PubMed] [Google Scholar]
  • 136.Bellgowan PS, Helmstetter FJ. Neural systems for the expression of hypoalgesia during nonassociative fear. Behav Neurosci. 1996;110:727–736. doi: 10.1037/0735-7044.110.4.727. [DOI] [PubMed] [Google Scholar]
  • 137.Akil H, Young E, Walker JM, Watson SJ. The many possible roles of opioids and related peptides in stress-induced analgesia. Ann NY Acad Sci. 1986;467:140–153. doi: 10.1111/j.1749-6632.1986.tb14625.x. [DOI] [PubMed] [Google Scholar]
  • 138.Lewis JW, Cannon JT, Liebeskind JC. Opioid and nonopioid mechanisms of stress analgesia. Science. 1980;208:623–625. doi: 10.1126/science.7367889. [DOI] [PubMed] [Google Scholar]
  • 139.Terman GW, Lewis JW, Liebeskind JC. Two opioid forms of stress analgesia: studies of tolerance and cross-tolerance. Brain Res. 1986;368:101–106. doi: 10.1016/0006-8993(86)91046-2. [DOI] [PubMed] [Google Scholar]
  • 140.Finn DP, Beckett SR, Richardson D, Kendall DA, Marsden CA, Chapman V. Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. Eur J Neurosci. 2004;20:848–852. doi: 10.1111/j.1460-9568.2004.03509.x. [DOI] [PubMed] [Google Scholar]
  • 141.Suplita RL, Gutierrez T, Fegley D, Piomelli D, Hohmann AG. Endocannabinoids at the spinal level regulate, but do not mediate nonopioid stress-induced analgesia. Neuropharmacology. 2005;262:25–25. doi: 10.1016/j.neuropharm.2005.10.007. [DOI] [PubMed] [Google Scholar]
  • 142.Heinricher MM, Morgan MM, Tortorici V, Fields HL. Disinhibition of off-cells and antinociception produced by an opioid action within the rostral ventromedial medulla. Neuroscience. 1994;63:279–288. doi: 10.1016/0306-4522(94)90022-1. [DOI] [PubMed] [Google Scholar]
  • 143.Smith PB, Martin BR. Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia. Brain Res. 1992;578:8–12. doi: 10.1016/0006-8993(92)90222-U. [DOI] [PubMed] [Google Scholar]
  • 144.Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther. 1992;262:10–18. [PubMed] [Google Scholar]
  • 145.Welch SP, Thomas C, Patrick GS. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther. 1995;272:310–321. [PubMed] [Google Scholar]
  • 146.Yaksh TL. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J Clin Pharmacol. 1981;21:334S–340S. doi: 10.1002/j.1552-4604.1981.tb02612.x. [DOI] [PubMed] [Google Scholar]
  • 147.Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 1998;345:145–153. doi: 10.1016/S0014-2999(97)01621-X. [DOI] [PubMed] [Google Scholar]
  • 148.Cannich A, Wotjak CT, Kamprath K, Hermann H, Lutz B, Marsicano G. CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn Mem. 2004;11:625–632. doi: 10.1101/lm.77904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149.Bernard JF, Bester H, Besson JM. Involvement of the spinoparabrachio-amygdaloid and-hypothalamic pathways in the autonomic and affective emotional aspects of pain. Prog Brain Res. 1996;107:243–255. doi: 10.1016/S0079-6123(08)61868-3. [DOI] [PubMed] [Google Scholar]
  • 150.Katona I, Rancz EA, Acsady L, et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci. 2001;21:9506–9518. doi: 10.1523/JNEUROSCI.21-23-09506.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 151.Connell K, Bolton N, Olsen D, Piomelli D, Hohmann AG. Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neurosci Lett. 2005;12:22–22. doi: 10.1016/j.neulet.2005.12.008. [DOI] [PubMed] [Google Scholar]
  • 152.Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci. 2000;12:533–539. doi: 10.1046/j.1460-9568.2000.00929.x. [DOI] [PubMed] [Google Scholar]
  • 153.Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 1999;83:137–145. doi: 10.1016/S0304-3959(99)00082-2. [DOI] [PubMed] [Google Scholar]
  • 154.Portenoy RK, Foley KM. Chronic use of opioid analgesics in nonmalignant pain: report of 38 cases. Pain. 1986;25:171–186. doi: 10.1016/0304-3959(86)90091-6. [DOI] [PubMed] [Google Scholar]
  • 155.Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol. 2003;7:469–475. doi: 10.1016/S1367-5931(03)00079-6. [DOI] [PubMed] [Google Scholar]
  • 156.Yesilyurt O, Dogrul A, Gul H, et al. Topical cannabinoid enhances topical morphine antinociception. Pain. 2003;105:303–308. doi: 10.1016/S0304-3959(03)00245-8. [DOI] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES